Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.

Agathe BérangerAdrie BekkerBelén P SolansMark F CottonMark MirochnickAvy ViolariJiajia WangMae CababasayLubbe WiesnerRenee BrowningJack MoyeEdmund V CapparelliRadojka M Savic

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

In LBW/preterm infants, INH dosing needs frequent adjustment to account for growth and maturation. Pharmacogenetics-based dosing regimens is the most powerful approach to deliver safe and equalized exposures for all infants, because NAT2 genotype highly impacts INH pharmacokinetic variability.

Keyphrases

preterm infants
human immunodeficiency virus
low birth weight
antiretroviral therapy
hepatitis c virus
human milk
hiv infected
hiv positive
hiv aids
preterm birth
mycobacterium tuberculosis
air pollution
hiv testing
men who have sex with men